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Background and aim: Antiviral therapy with peg-interferon and ribavirin induces sustained 
virus eradication in 40%–80% of patients with chronic hepatitis C virus (HCV). We investigated 
patient views on their involvement in therapeutic decision making and on the desirability of 
disease and treatment-related outcomes.
Methods: The control preferences and visual analog scales were administered in a pencil and paper 
format to a series of 45 patients in order to assess their decisional role, preferences for scenarios of 
HCV disease and antiviral treatment, and estimates of success required to recommend treatment.
Results: The preferred decisional role of patients was passive in 26 (58%), collaborative in 
12 (27%) and active in 7 (15%). Median preference scores ranged from 0.30 to 0.90 for sce-
narios of disease, from 0.05 to 0.80 for side effects and from 25% to 100% for estimates of 
benefit to recommend treatment.
Conclusions: Our patients prefer to defer to the doctor the final decision in starting therapy in 
a context of shared decision making. Reported preferences for HCV scenarios are in the range 
discussed in the literature. The wide variability in the values attributed to side effects by patients 
with chronic hepatitis C as well as in expected probabilities of successful treatment suggests a 
need for decision analysis tailored to the individual patient.
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Introduction
Hepatitis C virus (HCV) infection affects 170 million people worldwide (four million 
in USA and about five million in western Europe).1,2 Although the majority of those 
with chronic hepatitis C infection are not going to develop complications, 15%–40% 
may develop cirrhosis, liver failure, or hepatocellular carcinoma (HCC).3 Chronic 
hepatitis C is generally asymptomatic but has been associated with reduced health-
related quality of life in the early stages.4 Standard therapy is represented by combined 
use of pegylated interferon and ribavirin for 3–12 months. Such a regimen benefits 
40%–80% of patients, depending on HCV genotype,5 and has been shown to be 
cost-effective from a societal perspective.6
Perception of health by patients with HCV infection or harm from antiviral therapy 
strongly depends on the information given during the medical examination. It has been 
shown that the patient’s treatment decisions are influenced by multiple factors besides 
the risks and benefits of antiviral therapy or the physician’s recommendations. Social 
issues, some heuristics, particular conceptualizations of the illness, and considering 
therapy as a protected value are all factors which determine the patient’s acceptation 
or refusal of therapy.7Patient Preference and Adherence 2009:3 364
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The patient’s perspective is becoming more important in 
health care policy decisions worldwide. It is also becoming 
more and more common for patients to take an active role 
when medical decisions have to be made.8 Research on cancer 
suggests that role preferences vary considerably and that 
whilst most patients prefer a collaborative role, a significant 
minority prefer a passive or active role.9 To our knowledge no 
information exists regarding the common decision-making 
roles of patients with chronic hepatitis C in approaching a 
decision about treatment.
It is also well known that each individual patient 
provides different information about his/her own health 
state or disabilities, thus disclosing different preferences in 
drug therapy decisions with uncertain outcomes.10,11 Utility 
measurement is a method of determining an individual’s 
preference for a certain outcome represented by a quantitative 
score (utility). A systematic review of the available litera-
ture on health-state utilities for liver disease has been very 
recently published, producing estimates for major states of 
hepatitis C such as moderate disease, compensated cirrhosis, 
decompensated cirrhosis, and post-liver transplant.12
Both the desired/perceived decision-making role and 
the patient’s views on desirability of disease and treatment-
related outcomes are factors influencing the decision to start 
therapy and may be relevant for a perspective of shared deci-
sion making in chronic hepatitis C as in other clinical settings. 
To gain insight into these issues, we planned a pilot study to 
administer to a consecutive series of patients a questionnaire 
evaluating in a simple way their health status, the role they 
feel to play in decision making about antiviral therapy, and 
their preferences for some health scenarios related to chronic 
HCV and its treatment.
Materials and methods
The research protocol was approved by the local Ethical 
Committee. Participation in our study was proposed to a 
consecutive series of outpatients with biopsy proven chronic 
hepatitis C eligible for an Italian multicenter observational 
outcome study of pegylated interferon (alfa-2a or alfa-2b) 
and ribavirin.13
Eligibility criteria were: age 18–65 years; serum alanine 
aminotransferase ALT above the upper normal limit for at 
least six months; anti-HCV sero-positivity and detectable 
HCV viremia. Patients were treatment-naïve or previous 
relapsers or nonresponders and had clinical findings and 
laboratory parameters indicative of compensated liver 
disease. None had evidence of an ongoing cause of liver 
disease other than HCV .
Forty-five patients agreed to participate and provided 
written informed consent before entry into the study. 
A questionnaire was administered during the first visit 
after the diagnostic work-up, before starting treatment. 
In our clinical practice, it is during this visit that harm and 
benefit of antiviral therapy are thoroughly discussed with 
the patient in order to get informed consent to treatment. 
We formalized this approach and surveyed patients, using a 
pencil-and-paper format, by a questionnaire that consisted 
of five parts including:
1.  Demographic data consisting of age, gender, level of 
education, employment and marital status;
2.  A simple assessment of health status;
3.  An assessment of decision-making role through the 
choice of one among five statements, according to the 
control preferences scale14 (see Appendix 1);
4.  An evaluation of patient’s preferences (utilities) for six 
health scenarios with HCV, according to Cotler and 
colleagues.15 Utilities were assessed by asking to each 
patient to indicate a judgment of relative desirability 
of each scenario by placing a mark on a visual analog 
scale (VAS) ranging from 0 (death) to 1 (health without 
hepatitis C). Scenarios described four possible disease 
outcomes (chronic hepatitis or cirrhosis without and with 
symptoms) and two treatment outcomes (adverse events, 
sustained response) that would be part of any discussion 
on benefit and harm of antiviral therapy for chronic 
hepatitis C. The study instrument published by Cotler 
and colleagues15 was translated in Italian and slightly 
modified by excluding the health state 3 “hepatitis C with 
moderate symptoms, no cirrhosis”, and by including a 
scenario representing sustained response (see Appendix 2 
for descriptions).
5.  Patient’s judgment of what threshold of probability of 
treatment success they would consider minimally accept-
able to start drug treatment. This judgment was indicated 
by placing a mark on a VAS representing probabilities of 
achieving sustained viral eradication ranging from 0% 
to 100%.
The content of the descriptions and response scales of the 
study instrument have been tested for clarity, comprehension, 
and relevance in physicians and patients from the United 
States.15
All analyses were carried out using StatsDirect statistical 
software (version 2.6.1, 19.1.2007; StatsDirect, Cheshire, UK) 
and STATA software (v. 8.0; Stata Corporation, College 
Station, TX, USA). Box plots were used to describe patient’s 
preference values (utilities).Patient Preference and Adherence 2009:3 365
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Results
Patient demographic data and disease characteristics are 
summarized in Table 1. The majority of patients were naïve, 
infected with genotype 1, and highly viremic. Cirrhosis 
was present at histology in 14 patients (31%). Almost 70% 
of patients had a high school educational level and a full 
employment status. Accordingly, all patients completed the 
first three parts of the questionnaire. However, five patients 
(11%) refused to complete the assessment of utilities of 
clinical scenarios because of “tiredness and confusion” and 
four (9%) were excluded because of illogical assessment 
(ie, value for cirrhosis higher than value for asymptomatic 
chronic hepatitis).
Assessment of health status was good to excellent in 90% 
of patients (Figure 1). Only a minority of patients (15%) 
preferred an active decisional role, that is they favored a 
personal decision about therapy fully independent from the 
doctor’s opinion, and almost one third agreed for a shared 
decision (collaborative role). On the other hand, almost 60% 
of patients stated that the decision to start therapy is a matter 
of judgment for the health professional.
The descriptive statistics of preference values obtained from 
36 patients is reported in Figures 2 and 3. As expected, median 
values decreased consistently between asymptomatic and 
symptomatic chronic hepatitis and cirrhosis. The distribution 
of median utility values, reported within the box plots, showed 
declining patient’s estimates from the status scenario 1 (0.90) 
to the status scenario 4 (0.30). In other words patients assigned 
decrements of quality of life from 10% in asymptomatic 
chronic hepatitis to 70% in symptomatic cirrhosis. Looking 
at quartiles and range of estimates for each scenario, a large 
variability is evident in Figure 3 particularly for scenario 
describing side effects of treatment (range 0.05 to 0.80). The 
probability of treatment success that the patient considered 
Table 1 Baseline characteristics of 45 enrolled patients
Age 52 ± 12
sex male 30 (67%)
Risk factors
  – Transfusion 5 (11%)
  –  iDU 0
  –  Unknown 40 (89%)
Education level
  –  elementary school 17 (37%)
  –  high school 17 (37%)
  –  University or college 7 (15%)
  –  Professional/graduate 4 (9%)
Employment status
  –  Full time 29 (64%)
  –  Part-time 9 (20%)
  –  not employed 6 (13%)
  –  Retired 1 (2%)
Co-morbidity
  –  Diabetes 10 (22%)
  –  hypertension 10 (22%)
  –  hypothyroidism 2 (4%)
  –  Other 4 (9%)
naïve 33 (74%)
Previous treatment 12 (26%)
Histology
  –  cirrhosis 14 (31%)
Biochemical/virological parameters
  –  hb 15 (1.2)
  – WBc 6,300 (1,682)
  –  PLT 194,911 (58,032)
  – ALT × UnL 2.5 (1.8)
Virological parameters
  –  hcV viremia (Ui/ml)* 586790 (19,110–6,534,500)
  –  genotype 1–4 37 (82%)
  –  genotype 2–3 8 (18%)
Note: *Bayer (median and range).
Abbreviations: ALT,  alanine aminotransferase; iDU, intrauterine device; hcV, hepatitis c 
virus; PLT, platelet; UnL, upper normal limit;   WBc, white blood cells.
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to recommend treatment that showed wide estimates ranging 
from 25% to 100% (Figure 4).
Discussion
Current health care policy advocates patient participation in 
treatment decision making. In this pilot study we explored 
the preferred level of involvement in treatment decisions of 
a small series of patients from Italy with chronic hepatitis 
C, and used utility-based methods to measure how they 
valued the health states or disabilities that result from such 
disease and its treatment. Chronic hepatitis C is a long-term 
condition in which self-management and participation in 
CH, no symptoms
CH, symptoms
0 20 40 60 80 100
CIRR, mild symptoms
CIRR, mod to sev symptoms
min -[ lower quartile - median - upper quartile ]- max 
Figure 2 Box plots of preference values for hcV disease outcomes assessed by visual analog score.
Abbreviation: ch, chronic hepatitis; ciRR, cirrhosis; hcV, hepatitis c virus. 
Figure 3 Box plots of preference values for hcV treatment’ outcomes assessed by visual analog score.
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treatment decision making must be encouraged. Because the 
communication skills of professionals are central to facilitating 
patient participation we used a simple approach by selecting 
well known user-friendly instruments. We underline that 
many respondents in this study identified communication as 
an area requiring improvement, and many would have liked 
to be more involved in treatment decision making.
Our findings confirm the results of previous studies8,9,16,17 
showing that respondents had identifiable preferences, from 
active through to passive, regarding their level of participation 
in treatment decision making. In general, patients wish to 
be more involved in decisions regarding a minor illness 
more than a major illness,18 and women tend to desire more 
involvement than do men in clinical decisions.19 In our study, 
most patients felt they had little or no role in treatment 
decisions. Near 60% of them most preferred one of the 
passive decisional roles from the control preference scale. 
However, the most passive option was least preferred by more 
than half of respondents and almost 30% of respondents 
chose the D option which involves some, if limited, patient 
involvement, rather than the E option where the patient 
entirely defers decision making to health professionals. Thus, 
most respondents preferred some input into decision making. 
Typically, this extended to individuals feeling included in the 
decision and having their views respected.
Overall, while most patients were happy to defer overall 
control of treatment decision making to doctors, our data 
supports the notion of partnership. Our results are close with 
those of a study evaluating patients with hemato-oncological 
diseases showing that 60% among 117 interviewed patients 
desired more a passive than an active role.20 Moreover, in 
a telephone survey of elderly patients with chronic heart 
failure 21% of patients preferred an active role versus 31% 
favoring a collaborative role and 48% a passive role in 
decision making.21
According to a previous study15 we used utility analysis 
to evaluate patient’s perceptions of hepatitis C-related health 
states and patient’s threshold to recommend treatment. 
Although the rating scale method does not have its roots in 
expected utility theory, ie, it is not strictly utility, we believe 
it is similar to and has measurement advantages over true 
utilities.14 We found that the majority of patients understood 
descriptions of health states and were able to provide an utility 
assessment of the scenarios using a VAS. The validity of the 
health state construct was supported by the significant decline 
of utilities assigned with increasing health state severity 
(from chronic hepatitis to cirrhosis). Although derived from 
Table 2 Assessment of decision-making role by cPs
Patient alone 0
Patient primarily 7 (15%)
shared equally 12 (27%)
Doctor primarily 13 (29%)
Doctor alone 13 (29%)
Abbreviation: cPs, control preferences scale.
Figure 4 Box plots of patient’ estimates of benefit to recommend antiviral treatment.
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a small sample our estimates are similar to those reported in 
previous studies which have directly assessed utilities from 
patients by using the rating scale method as well as other 
methods (Table 3).
Potential factors causing variability of utility estimates 
could be due to both the tool used (VAS generates the 
lowest estimates of all the methods, with standard gamble 
and time trade-off having much higher estimates), the 
type of respondent (patients, nondiseased subjects, health 
professionals), and geographical and cultural differences. We 
recruited individuals from a tertiary care setting representing 
a population of European HCV-infected patients with no 
known risk factors eligible for antiviral treatment. The results 
derived from this convenience sample might be different from 
those that could have been derived should have the sample 
been randomly drawn from all eligible participants in the 
general population with chronic HCV infection.
It is of interest that the median rating for life with side 
effects of antiviral therapy was 0.25, suggesting a perceived 
75% reduction from good health during time on therapy. 
Thus, patients viewed side effects unfavorably at least in 
the proposed scenario. Moreover, the large range of patient 
ratings is striking and indicate that patient views about the 
impact of side effects on health status varies substantially. 
We don’t know the difference in disutility of each patient 
among different adverse events, ie, flu-like versus depression 
or alopecia, or the value patients could assign to possible 
life-threatening adverse event such as a severe infection. 
This information is lacking in the literature but it is very 
important for the generation of recommendations for 
treatment.25 As the ratings of adverse events overlap with the 
ratings of future disease scenarios (without or with symptoms) 
and as patients’ estimates of benefit in recommended treat-
ment are also largely variable, it seems that decision analysis 
could be of help in decision making.
The strength of our study include the novelty of assessing 
hepatitis C patient views on their role in therapeutic decision 
making by means of established scales. In fact, to our 
knowledge, this was not assessed previously in a population 
of liver patients. However, our study suffers from some 
methodological limitations such an unique geographical 
location and a limited sample size, so that characteristics of 
small subgroups could not be investigated. Evidence of the 
association of factors such age, gender, level of education, 
marital status, socioeconomic status, and health status with 
preferences for involvement in treatment decision making or 
with health utilities of patients with chronic hepatitis C remain 
inconclusive and should be assessed in future studies.
In conclusion, our patients prefer to defer to the doctor 
the final decision in starting therapy in a context of shared 
decision making. Preferences for HCV scenarios are in the 
range reported in the literature. The wide variability in the 
values attributed by patients with chronic hepatitis C to 
both scenarios of health with HCV and health with antiviral 
treatment as well as in expected probabilities of cure suggests 
a need for decision analysis tailored to the individual patient. 
Further research is needed to identify predictors of preferences 
for active or passive patient roles and further utility analysis 
is needed to generate data on the values patients assign to 
single side effects from antiviral therapy.
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Appendix 1 Decision-making role by control preferences scale
Which of the following is closest to your feeling about the role you feel you should have in your medical decision about treatment of 
chronic hepatitis c?
A. I would prefer to make the final decision about which treatment I will receive on the basis of the facts I learn from my physician’s opinion
B. I would prefer to make the final decision about my treatment after considering my physician’s opinion
c. i would prefer that my physician and i share responsibility for deciding which treatment is best for me
D. I would prefer that my physician make the final decision about which treatment will be used but he or she seriously consider my opinion
e. i would prefer to leave all decisions regarding treatment to my physician
Appendix
Appendix 2 Description of six scenarios of health with HCV (Cotler, modified)
1.   Asymptomatic chronic hepatitis, no cirrhosis
  Absence of symptoms
  Transmission to sexual partner possible
  May progress to cirrhosis
2. Symptomatic chronic hepatitis, no cirrhosis
  sometimes do not feel rested
  Tire more easily than usual
  Limitation of physical activity possible
  Transmission to sexual partner possible
  May progress to cirrhosis
3. Chronic hepatitis with cirrhosis, mild symptoms
  sometimes do not feel rested
  Tire more easily than usual
  Limitation of physical activity possible
  Transmission to sexual partner possible
  have cirrhosis
  May get liver cancer
  May get liver failure
4. Cirrhosis, moderate to severe symptoms
  Usually feel tired
  Tire more easily than usual
  Limitation of physical activity possible
  Little interest in sex
  have cirrhosis
  May get liver cancer
  May get liver failure
  May need liver transplantation
5. Side effects from pegylated interferon and ribavirin
  needle stick one time a week
  Pills twice daily
  Flu-like symptoms (fever, chills, nausea, headache, poor appetite) that tend to improve after 2 weeks
  Tiredness, difficulty in sleeping, irritability, difficulty in concentrating
  chance of other non life-threatening problems that go away after treatment is completed, such as low blood count, hair loss and depression
6. Sustained response to treatment
  Absence of symptoms
  Transmission to sexual partner unlikely
  Progression to cirrhosis very likely reduced